| Abstrakt: |
Axonics, Inc., a global medical technology company, has reported its financial results for the fourth quarter and fiscal year of 2023. The company experienced strong growth, with a 34% increase in revenue in 2023 and a gross margin of nearly 75%. Axonics therapies were used by clinicians to treat approximately 100,000 incontinence patients globally in 2023. The company's net revenue for the fourth quarter of 2023 was $109.7 million, with sacral neuromodulation revenue accounting for $88.5 million and Bulkamid revenue accounting for $21.2 million. Axonics ended the year with cash, cash equivalents, short-term investments, and restricted cash totaling $358 million. [Extracted from the article] |
